RTP Mobile Logo
What Clinicians Want To Know: Addressing the Most Common Questions and Controversies in the Current Clinical Management of Select Gastrointestinal Cancers
Released May 2012

Proceedings from a CME symposium held at the 2012 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Charles S Fuchs, Axel Grothey, Daniel G Haller, Eileen M O’Reilly, Eric Van Cutsem and Alan P Venook. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of gastrointestinal (GI) cancers.

    OVERVIEW OF ACTIVITY

    Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Of interest, however, although individually less frequently encountered, the collection of other “non-CRC” GI cancers accounts for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined. Local and systemic treatment approaches for these cancers are continuously evolving. The effects of novel molecular-targeted and biologic therapies on the management of non-CRC GI cancers have been profound and in some instances have changed best-practice care. Thus, in addition to maintaining a sound understanding of the conventional but distinct treatment algorithms applicable to each subtype of GI cancer, practicing oncologists must now rationally integrate targeted agents into their individualized therapeutic recommendations for the safe and effective clinical management of diseases they seldom encounter. To bridge the gap between research and patient care, these proceedings from a CME symposium at the 2012 Gastrointestinal Cancers Symposium use the perspectives of clinical investigators to apply evidence-based concepts to routine practice. By providing access to the latest research developments and expert opinions on these diseases, this activity will assist medical oncologists and other healthcare providers in the formulation of up-to-date clinical management strategies for GI cancers.

    LEARNING OBJECTIVES

    • Apply the results of emerging clinical research to the best-practice management of select GI cancers originating within and outside of the colon and rectum.
    • Counsel patients with Stage II colon cancer about their individual risk of recurrence based on clinical, pathologic and genomic biomarkers, and consider adjuvant therapeutic options.
    • Individualize local and systemic treatment for patients with metastatic CRC that is isolated to the liver.
    • Communicate the benefits and risks of anti-VEGF and anti-EGFR biologic therapy to patients with metastatic CRC.
    • Utilize clinical and molecular biomarkers to select optimal treatment strategies for patients with gastric cancer.
    • Effectively integrate the evidence-based use of chemotherapy and molecular-targeted agents into the individualized management of advanced pancreatic cancer.
    • Communicate the benefits and risks of existing and emerging systemic interventions to patients with locally advanced or metastatic hepatocellular carcinoma.
    • Recall new data with investigational agents demonstrating promising activity in diverse GI cancers.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY

    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GICancers12/CME.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Charles S Fuchs, MD, MPH
    Director, Center for Gastrointestinal Cancer
    Dana-Farber/Harvard Cancer Center
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Pfizer Inc, Roche Laboratories Inc, Sanofi; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Pfizer Inc, Roche Laboratories Inc, Sanofi.

    Axel Grothey, MD
    Professor of Oncology
    Department of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    Paid Research: Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech BioOncology.

    Daniel G Haller, MD
    Professor of Medicine
    Deenie Greitzer Professor of Gastrointestinal Oncology
    Abramson Cancer Center at the University of Pennsylvania
    Philadelphia, Pennsylvania

    Advisory Committee: Genentech BioOncology, Novartis Pharmaceuticals Corporation, Sanofi; Consulting Agreements: Genomic Health Inc, Novartis Pharmaceuticals Corporation; Independent Data Monitoring Committee: ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company.

    Eileen M O'Reilly, MD

    Associate Attending
    GI Medical Oncology Service
    Memorial Sloan-Kettering Cancer Center
    Associate Professor of Medicine
    Weill Medical College of Cornell University
    New York, New York

    Consulting Agreements: Abbott Laboratories, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celsion Corporation, Chugai Pharmaceutical Co Ltd, Clovis Oncology, Daiichi Sankyo Inc, Genentech BioOncology, GenVec Inc, Halozyme Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Jennerex Inc, MediGene Inc, Merck and Company Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi; Paid Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Chugai Pharmaceutical Co Ltd, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, MediGene Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Polaris Group.

    Eric Van Cutsem, MD, PhD
    Professor of Medicine
    Digestive Oncology
    University Hospital Gasthuisberg/Leuven
    Leuven, Belgium

    Research Grants: Amgen Inc, Merck Serono, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc.

    Alan P Venook, MD
    Professor of Clinical Medicine
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: Myriad Genetics Inc; Paid Research: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, GlaxoSmithKline.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Regeneron Pharmaceuticals and Sanofi.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2012
    Expiration date: May 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WiFi is recommended for best performance)
Introduction: Dr Love
Module 1:
Professor Van Cutsem
Gastric Cancer
Module 2:
Dr Haller
(Neo)Adjuvant Therapy of Colorectal Cancer
Module 3:
Dr Venook
Hepatocellular Carcinoma
Module 4:
Dr Grothey
Management of Isolated CRC Metastases
Module 5:
Dr O’Reilly
Pancreatic Adenocarcinoma
Module 6:
Dr Fuchs
Advanced Colon Cancer